BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

...coenzyme A biosynthesis caused by a mutant pantothenate kinase 2 (PANK2; NBIA1) gene. Sandi Wong, Staff Writer fosmetpantotenate (RE-024) Retrophin Inc. Pantothenate kinase 2 (PANK2) (NBIA1) Neurology...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BioCentury | Jun 19, 2019
Financial News

Coenzyme A company Comet debuts with $28.5M series A

...Kuscer. TM3 was developing a metabolite in the coenzyme A biosynthesis pathway to overcome pantothenate kinase 2 (PANK2...
...de Graaf and Van Vlasselaer joined Comet's board. Mary Romeo, Staff Writer Canaan Comet Therapeutics Inc. Sofinnova Partners TM3 Therapeutics B.V. Pantothenate kinase 2 (PANK2) (NBIA1) coenzyme...
BioCentury | Apr 18, 2019
Distillery Therapeutics

Lanthipeptide-based antibiotics for Gram-positive bacterial infections

DISEASE CATEGORY: Infectious disease INDICATION: Gram-positive bacterial infection; Staphylococcus; Enterococcus; Streptococcus Cell culture studies identified multiple lanthipeptide-based antibiotics that could help treat Gram-positive bacterial infections. Screening in cell-based growth assays of a library of compounds...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Nov 6, 2018
Distillery Therapeutics

Neurology

...a PANK3 activator that could help treat pantothenate kinase-associated neurodegeneration (PKAN), which is caused by PANK2...
...PANK3 activation, in a human liver cell line compared with an inactive analog. In a PANK2-knockout...
...of an optimized version of the compound in 2019. TARGET/MARKER/PATHWAY: Pantothenate kinase 3 (PANK3); PANK2 (NBIA1...
BioCentury | Jul 12, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jun 15, 2018
Company News

BridgeBio launches rare genetic disorder subsidiary

...product, a phosphopantothenate molecule that restores disruption in coenzyme A biosynthesis caused by a mutant PANK2...
...preclinical testing. The candidate is a metabolite in the coenzyme A biosynthesis pathway that overcomes PANK2...
BioCentury | Jun 13, 2018
Company News

BridgeBio launches rare genetic disorder subsidiary

...product, a phosphopantothenate molecule that restores disruption in coenzyme A biosynthesis caused by a mutant PANK2...
...preclinical testing. The candidate is a metabolite in the coenzyme A biosynthesis pathway that overcomes PANK2...
...see BioCentury, Sept. 15, 2017) . Chris Lieu fosmetpantotenate (RE-024) P-PantSAc (TM-1803) BridgeBio Pharma LLC Retrophin Inc. St. Jude Children's Research Hospital Pantothenate kinase 2 (PANK2) (NBIA1) Neurology...
BioCentury | Sep 20, 2017
Distillery Therapeutics

Neurology

...with chemical-induced PANK2 deficiency and a Drosophila embryonic cell line with chemical-induced PANK2 deficiency or PANK2...
...knocked down, acetyl-phosphopantetheine increased viability compared with no treatment. In a mouse model of chemical-induced PANK2...
...testing acetyl-phosphopantetheine in induced pluripotent stem (iPS) cell-derived neurons from PKAN patients. TARGET/MARKER/PATHWAY: Pantothenate kinase 2 (PANK2; NBIA1...
Items per page:
1 - 10 of 24